COMBINATION DRUG FOR TREATING TRIPLE-NEGATIVE BREAST CANCER
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
N/A
Issued Date -
Mar 13, 2025
app pub date -
Nov 18, 2024
filing date -
Nov 18, 2024
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
A combination drug for treating triple-negative breast cancer. Androgen receptor-targeting degraders (including PROTACs) can effectively prevent and/or treat triple negative breast cancer (including androgen receptor-positive triple negative breast cancer). The combined use of an androgen receptor degrader and a targeting drug (including PI3Kα inhibitors and PARP inhibitors), immunotherapy drug or chemotherapy drug can effectively prevent and/or treat triple negative breast cancer.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully